Sofosbuvir Effects on the Eye
RemonGirgisLamee;
Abstract
Egypt has the highest HCV prevalence in the world, 10%-20% of the general population is infected and HCV is the leading cause of chronic liver disease and HCC in the country.
HCV is known as the “silent epidemic” because patients may have no symptoms during the first 20-30 years after infection. However, the infection will slowly damage their liver over time.
Hepatic retinopathy is a condition at which retinal dysfunction occurs in patients with liver insufficiency. It is mostly due to high serum levels of ammonia that exceed the detoxifying capability of the Muller cell which is the main macroglial cell in the retina.
Until 2011, the combination of pegylated interferon (PegIFN) and ribavirin for 24 or 48 weeks was the approved treatment for chronic hepatitis C.
Three new HCV DAAs have been licensed in the Europe in 2014, for use as part of combination therapies for HCV infection.
Sofosbuvir, a pangenotypic nucleotide analogue inhibitor of HCV RNA-dependent RNA polymerase, has been approved in January 2014. Simeprevir, a second-wave, first-generation NS3-4A protease inhibitor active against genotypes 1 and 4 has been approved in May 2014. Daclatasvir, a pangenotypic NS5A inhibitor, has been approved in August 2014.
HCV is known as the “silent epidemic” because patients may have no symptoms during the first 20-30 years after infection. However, the infection will slowly damage their liver over time.
Hepatic retinopathy is a condition at which retinal dysfunction occurs in patients with liver insufficiency. It is mostly due to high serum levels of ammonia that exceed the detoxifying capability of the Muller cell which is the main macroglial cell in the retina.
Until 2011, the combination of pegylated interferon (PegIFN) and ribavirin for 24 or 48 weeks was the approved treatment for chronic hepatitis C.
Three new HCV DAAs have been licensed in the Europe in 2014, for use as part of combination therapies for HCV infection.
Sofosbuvir, a pangenotypic nucleotide analogue inhibitor of HCV RNA-dependent RNA polymerase, has been approved in January 2014. Simeprevir, a second-wave, first-generation NS3-4A protease inhibitor active against genotypes 1 and 4 has been approved in May 2014. Daclatasvir, a pangenotypic NS5A inhibitor, has been approved in August 2014.
Other data
| Title | Sofosbuvir Effects on the Eye | Other Titles | تأثير عقار السوفوسبوفير علي العين | Authors | RemonGirgisLamee | Issue Date | 2017 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.